Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880731 | 0.90 | MAPK14 (0.51) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL1883729 | 0.84 | MAPK14 (0.50) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL1883542 | 0.84 | MAPK14 (0.66) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL1880113 | 0.80 | MAPK14 (0.67) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL1880870 | 0.79 | MAPK14 (0.65) | MAPK14LCKCYP2C9CYP2C19KIT | |
| SCHEMBL13692227 | 0.78 | MAPK14 (0.36) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL12671933 | 0.75 | MAPK14 (0.39) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL3667389 | 0.74 | MAPK14 (0.79) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL1879539 | 0.73 | MAPK14 (0.65) | MAPK14CYP3A4LCKCYP2C9CYP2C19 | |
| SCHEMBL1886774 | 0.73 | MAPK14 (0.66) | MAPK14CYP3A4LCKCYP2C9KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367671-B2 | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents | AMGEN INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367671-B2 | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents | AMGEN INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2009117156-A1 | PYRAZOLO-PYRAZINONE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | MAPK1, MAP3K1, MAP4K2 | MAPK14 32/4885CYP3A4 1121/4885LCK 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.